Technical Analysis for CASI - CASI Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.66 5.73% 0.09
CASI closed down 7.65 percent on Tuesday, April 20, 2021, on 78 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 10
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical CASI trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 5.73%
Below Lower BB Weakness 5.73%
Down 3 Days in a Row Weakness 5.73%
Down 4 Days in a Row Weakness 5.73%
Down 5 Days in a Row Weakness 5.73%
Lower Bollinger Band Touch Weakness 5.73%
Oversold Stochastic Weakness 5.73%
Expansion Breakdown Bearish Swing Setup -2.35%
Reversal New Lows Setup Bearish Swing Setup -2.35%
Wide Bands Range Expansion -2.35%
Older End-of-Day Signals for CASI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 2 hours ago
60 Minute Opening Range Breakout about 3 hours ago
Up 3% about 3 hours ago
Up 2% about 3 hours ago
Down 1% about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


CASI Pharmaceuticals, Inc. Description

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.


Keywords: Biotechnology Cancer Life Sciences Pharmaceutical Diseases Solid Tumors Treatment Of Cancer Autoimmune Diseases Autoimmune Disease Ovarian Cancer Stage Pharmaceutical Cancer Treatment Platinum Leukemia Multiple Myeloma Advanced Solid Tumors Cell Cycle Cyclacel Pyrrolidines Pacritinib

Is CASI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.9
52 Week Low 1.46
Average Volume 1,301,827
200-Day Moving Average 2.26
50-Day Moving Average 2.36
20-Day Moving Average 1.99
10-Day Moving Average 1.87
Average True Range 0.15
ADX 30.44
+DI 11.84
-DI 34.48
Chandelier Exit (Long, 3 ATRs ) 1.98
Chandelier Exit (Short, 3 ATRs ) 2.03
Upper Bollinger Band 2.38
Lower Bollinger Band 1.60
Percent B (%b) -0.04
BandWidth 39.06
MACD Line -0.19
MACD Signal Line -0.16
MACD Histogram -0.0263
Fundamentals Value
Market Cap 194.59 Million
Num Shares 124 Million
EPS -0.44
Price-to-Earnings (P/E) Ratio -3.54
Price-to-Sales 21.49
Price-to-Book 3.28
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.77
Resistance 3 (R3) 1.79 1.75 1.74
Resistance 2 (R2) 1.75 1.70 1.74 1.72
Resistance 1 (R1) 1.66 1.66 1.64 1.64 1.71
Pivot Point 1.61 1.61 1.60 1.60 1.61
Support 1 (S1) 1.53 1.56 1.50 1.50 1.43
Support 2 (S2) 1.48 1.53 1.47 1.42
Support 3 (S3) 1.39 1.48 1.40
Support 4 (S4) 1.37